SCHEMBL1925664

SCHEMBL1925664

COc1ccc(C(=O)NC2CCCCC2)cc1Nc1nccc(Nc2c(NC(C)(C)C)c(=O)c2=O)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 12/20 0.47
BRD4 O60885 3/20 0.47
BRDT Q58F21 3/20 0.47
PLK3 Q9H4B4 5/20 0.46
PLK2 Q9NYY3 3/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
PTK2 Q05397 2/20 0.46
PRKD2 Q9BZL6 3/20 0.46
RPS6KA3 P51812 2/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PRKCG P05129 1/20 0.46
CLK2 P49760 1/20 0.46
NEK4 P51957 1/20 0.46
CAMK2G Q13555 1/20 0.46
CAMK2D Q13557 1/20 0.46
SRPK1 Q96SB4 1/20 0.46
CSNK1G1 Q9HCP0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1928456 0.88 PLK1 (0.52) PLK1BRD4BRDTPLK3PLK2
SCHEMBL1926374 0.87 LRRK2 (0.49) PLK1BRD4BRDTPLK3PLK2
SCHEMBL1925497 0.86 PLK1 (0.53) PLK1PLK3PLK2PRKD2RPS6KA3
SCHEMBL1927355 0.86 PLK1 (0.47) PLK1BRD4PLK3PLK2PTK2
SCHEMBL1927285 0.85 PLK1 (0.50) PLK1BRD4BRDTPLK3PLK2
SCHEMBL1926244 0.85 PLK1 (0.49) PLK1BRD4BRDTPLK3PLK2
SCHEMBL1925996 0.85 AURKA (0.47) PLK1PLK3PLK2PRKD2RPS6KA3
SCHEMBL1926343 0.84 USP30 (0.49) PLK1BRD4BRDTPLK3PLK2
SCHEMBL1926562 0.84 USP30 (0.53) PLK1BRD4BRDTPLK3PLK2
SCHEMBL1925997 0.83 PLK1 (0.48) PLK1BRD4BRDTPLK3PLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US claimed
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US disclosed
EP-2021316-A1 INHIBITORS OF POLO-LIKE KINASES Abbott Laboratories (US) 2009-02-11 EP disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 US disclosed
WO-2007140233-A1 INHIBITORS OF POLO-LIKE KINASES ABBOTT LABORATORIES (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES PLK1, PLK2, BUB1B PLK1 1/4885BRD4 1021/4885BRDT 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.